Related Experiment Videos
Bucindolol (Bristol-Myers Squibb Co)
1Istituto Chimica e Chimica Clinica, Catholic University, 00168 Rome, Italy. r.scatena@uniserv.ccr.rm.cnr.it
Idrugs : the Investigational Drugs Journal
|September 15, 2005
Summary
Bucindolol, a beta-blocker, is being investigated for hypertension and heart failure. Phase III clinical trials are underway to evaluate its efficacy and safety for these cardiovascular conditions.
Area of Science:
- Cardiovascular pharmacology
- Clinical drug development
Background:
- Bucindolol is a beta1 and beta2 adrenoceptor antagonist.
- It is under development for hypertension and congestive heart failure (CHF).
Purpose of the Study:
- To evaluate bucindolol as a potential treatment for hypertension.
- To assess bucindolol for congestive heart failure (CHF).
Main Methods:
- Phase III clinical trials are being conducted.
- The trials involve Intercardia, Knoll AG, and the National Institutes of Health (NIH).
Main Results:
- Results from phase III trials are pending.
- Previous development was ceased by Bristol-Myers Squibb in 1989.
Conclusions:
- Bucindolol shows potential for treating hypertension and CHF.
- Further clinical evaluation is ongoing.